- The Wall Street Journal•3 hours ago
Gilead Sciences’s approach to the biotech deals market involves more than just waiting.
- American City Business Journals•14 hours ago
Gilead Sciences Inc. spent $125 million for a voucher that could speed FDA review of a drug, but one analyst said the seller may have undervalued the asset. Sarepta Therapeutics of Cambridge, Mass., on Tuesday said it sold the so-called priority review voucher to Foster City-based Gilead Sciences Inc. (GILD). Sarepta (SRPT) had received the rare pediatric disease voucher when the Food and Drug Administration approved its Duchenne muscular dystrophy drug, Exondys51, in September.
- Investopedia•17 hours ago
Sarepta sold its Priority Review Voucher for $125 million to Gilead.
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
|Bid||69.25 x 400|
|Ask||69.29 x 100|
|Day's Range||68.83 - 70.00|
|52 Week Range||65.38 - 103.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.97|
|Dividend & Yield||2.08 (2.98%)|
|1y Target Est||N/A|